Market Size of Influenza Medications Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 5.30 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Influenza Medications Market Analysis
Influenza has been recognised as a crucial cause of morbidity and mortality in the human population, which is leading to the development of novel drugs that are intended for reducing consequent health and economic impacts. Increasing prevalence of influenza and growth in research funding for the development of new Medications are the major factors driving the global influenza Medications market.
According to the WHO, in 2018, influenza can cause severe sickness or death mainly in patients at a high risk and illness range from mild to severe and even death. In addition, this annual increase is projected to result in about 3-5 million cases of severe illness, and about 290,000-650,000 deaths, globally.
Additionally, the growing number of government initiatives to increase awareness about the Medications and prevention of influenza. presence of Strong Pipeline for Antiviral Drugs is the other factors that are propelling the growth of the market globally.
However, high costs and side effects associated with the influenza medications are likely to hamper the growth of the market.
Influenza Medications Industry Segmentation
Influenza, also known as flu, is a highly contagious infectious disease caused by a virus. This is an infection of the respiratory passages, which causes fever and severe aches.
| By Type | |
| Antiviral Drugs | |
| Antihistamines | |
| Vaccines | |
| Other |
| By Distribution Channel | |
| Hospital Pharmacy | |
| Independent Pharmacy and Drug Store | |
| Online Pharmacy |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Influenza Medications Market Size Summary
The influenza medications market is experiencing significant growth driven by the increasing prevalence of influenza and heightened research funding aimed at developing new treatments. The World Health Organization has highlighted the severe health impacts of influenza, particularly among high-risk populations, which has spurred the development of novel antiviral drugs and vaccines. Government initiatives to raise awareness and prevent influenza, along with a robust pipeline of antiviral drugs, are further propelling market expansion. Despite these advancements, the market faces challenges such as the high costs and potential side effects of influenza medications, which could impede growth.
In North America, the influenza medications market is poised for growth due to a strong healthcare system and proactive government efforts to manage influenza-related health issues. The Centers for Disease Control and Prevention's surveillance reports and frequent product launches, such as Lupin's generic Oseltamivir Phosphate capsules, underscore the region's commitment to combating influenza. Major industry players are expanding their presence through strategic partnerships and collaborations, with key developments like the FDA's approval of Roche's XofluzaTM highlighting ongoing innovation. The market's growth is supported by advancements in vaccine strategies and the collaborative efforts of organizations like the Human Vaccines Project, which aims to develop a universal influenza vaccine.
Influenza Medications Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rising Incedence and Prevalence of Influenza
-
1.2.2 Increasing R&D Initiatives in Development of Novel and Advanced Drugs for the Treatment of Influenza
-
-
1.3 Market Restraints
-
1.3.1 High cost of Drug Development
-
1.3.2 Side effects Asoociated with Antiviral Therapy
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Type
-
2.1.1 Antiviral Drugs
-
2.1.2 Antihistamines
-
2.1.3 Vaccines
-
2.1.4 Other
-
-
2.2 By Distribution Channel
-
2.2.1 Hospital Pharmacy
-
2.2.2 Independent Pharmacy and Drug Store
-
2.2.3 Online Pharmacy
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Influenza Medications Market Size FAQs
What is the current Influenza Medications Market size?
The Influenza Medications Market is projected to register a CAGR of 5.30% during the forecast period (2024-2029)
Who are the key players in Influenza Medications Market?
Sanofi , GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd.(Genentech USA, Inc.), Seqirus and NATCO Pharma Limited are the major companies operating in the Influenza Medications Market.
